Komori
Stella Pharma (4888) · PolicyRestated

Executive compensation policy consisting solely of fixed remuneration, with an emphasis on enhancing corporate value over the medium to long term

First written in FY2022. 1 of 3 entries say "Reframed", first in FY2025. Latest entry: FY2026.

3entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022ReframedFY20252022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Executive Compensation Policy and Design Combining Fixed and Share-Based CompensationA theme 89 companies write about · 12 as a headwind · 56 as a tailwind

The whole theme swung hardest in 2024: 8 of 45 companies on the "Worse" side.

26 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 89 companies compared. The sentences above are computed from all 89.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Each director's compensation consists of basic compensation as fixed compensation and performance-linked restricted stock compensation.」

    The Company continues to use a compensation structure combining fixed compensation and performance-linked restricted stock compensation.
  2. FY2025ReframedAnnual report

    「Each director's compensation consists of basic compensation as fixed compensation and performance-linked restricted stock compensation. The covered period is approximately 3 years, from 25 June 2024 to 31 May 2027. A share-price growth rate of 300% or more for the Company's common shares will constitute achievement of the numerical target.」

    The compensation structure changed from the previous policy of fixed compensation only to a combination of fixed compensation and performance-linked restricted stock compensation. The performance target is a 300% share-price growth rate.
  3. FY2022First statedAnnual report

    「Given the nature of the Company's business, which requires a long period to achieve monetisation, a compensation structure linked to shareholder interests would be desirable so that directors' compensation functions adequately as an incentive to achieve sustained growth in corporate value over the medium to long term, rather than rewarding short-term results. However, the Company only began manufacturing and selling pharmaceuticals in the previous fiscal year, and it would be difficult to introduce a compensation structure linked to performance indicators until its business foundation is firmly established. Accordingly, each director will receive only basic compensation as fixed compensation.」

    Describes a compensation policy consisting solely of fixed basic compensation, without performance-linked or non-monetary compensation, until the business foundation becomes stable.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Stella Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Executive compensation policy consisting solely of fixed remuneration, with an emphasis on enhancing corporate value over the medium to long term | STELLA PHARMA CORPORATION (4888) | Komori